The Safety and Efficacy of Pomalidomide in Combination With Cyclophosphamide and Dexamethasone (PCD) in the Transplant-ineligible Patients With Relapsed and/or Refractory Multiple Myeloma (MM)

Inclusion Criteria: * Patients must have evaluable multiple myeloma with at least one of the following (within 21 days of starting treatment) * Serum M-protein ≥ 0.5g/dL, or * In subjects without detectable serum M-protein, Urine M-protein ≥ 200mg/24 hour, or serum free light chai (sFLC) \> 100mg/L (involved light chain) and an abnormal kappa/Lambda ratio * Patients were ineligible for autologous stem cell transplantation * Must be relapse refractory to initial therapy with bortezomib, melphalan and prednison and then lenalidomide plus dexamethasone. * Refractoriness is defined as disease progression on treatment or progression within 6 months after the last dose of a given therapy. Relapse is defined according to the criteria of IMWG * Males and females ≥ 18 years of age or \> country's legal age for adult consent * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2 * Patients must meet the following clinical laboratory criteria with 21 days of starting treatment: * Absolute neutrophil count (ANC) ≥ 1,000/mm3 and platelet ≥ 50,000/mm3 (≥ 30,000/mm3 if myeloma involvement in the bone marrow is \>50%) * Total bilirubin ≤ 1.5 x the upper limit of the normal range (ULN). Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 x ULN. * Calculated creatinine clearance ≥ 30mL/min or creatinine \< 3mg/dL. * Written informed consent in accordance with federal, local and institutional guidelines Exclusion Criteria: * Female patients who are lactating or pregnant * Multiple Myeloma of IgM subtype * Glucocorticoid therapy (prednisolone \> 30mg/day or equivalent) within 14 days prior to informed consent obtained * POEMS syndrome, plasma cell leukemia or circulating plasma cells ≥ 2 x 109/L, Waldenstrom's Macroglobulinaemia, or Patients with known amyloidosis * Peripheral neuropathy grade \> 2 * Chemotherapy with approved or investigation anticancer therapeutics within 21 days prior to starting pomalidomide treatment * Focal radiation therapy within 7 days prior to start of pomalidomide. Radiation therapy to an extended field involving a significant volume of bone marrow within 21 days prior to start of pomalidomide * Immunotherapy (excluding steroids) 21 days prior to start of pomalidomide * Major surgery (excluding kyphoplasty) within 28 days prior to start of pomalidomide * Active congestive heart failure (New York Heart Association \[NYHA\] Class III or IV), symptomatic ischaemia, or conduction abnormalities uncontrolled by conventional intervention. Myocardial infarction within 4 months prior to informed consent obtained * Known HIV seropositive, hepatitis C infection, and/or hepatitis B (except for patients with hepatitis B surface antigen or core antibody receiving and responding to antiviral therapy directed at hepatitis B: these patients are allowed) * Second malignancy within the past 3 years except: * Adequately treated basal cell or squamous cell skin cancer * Carcinoma in situ of the cervix * Breast carcinoma in situ with full surgical resection * Patients with steroid or lenalidomide hypersensitivity * Patients with pleural effusions requiring thoracentesis or ascites requiring paracentesis within 14 days prior to starting pomalidomide treatment * Any clinically significant medical disease or psychiatric condition that, in the investigator's opinion, may interfere with protocol adherence or a patient's ability to give informed consent